PLSM 6-K SEC Filing Analysis

Latest settled — T+20d

PLSM ▲ +10.67% at T+20d

NEUTRAL call ✓ call won +10.67% · α vs SPY +10.64% · entry $3.75 → $4.15

Next anchor: T+60d in 8w

Currently $3.98 · +6.27% from $3.75 entry

Entry anchored
May 7, 2026
via day open

T+1d

0.00%

call 0.00% · α -0.23%

$3.75

settled 5w ago

T+5d

+17.07%

call +17.07% · α +15.60%

$4.39

settled 27d ago

T+20d

+10.67%

call +10.67% · α +10.64%

$4.15

settled 5d ago

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Pulsenmore filed a 6-K furnishing its proxy statement for the June 16, 2026 Annual General Meeting. The agenda includes routine director re-elections, approval of the CEO's 2026 bonus plan (with targets tied to cash burn, sales, fundraising, and FDA milestones), discretionary bonus payments for 2025 to the CEO ($22,500) and VP R&D ($3,500), and an amended compensation policy raising maximum salary and bonus ceilings. This is a routine governance filing with no material financial data, no earnings release, and no change to the company's financial outlook.

Actionable Insight

This is a routine proxy filing with no earnings or operational updates. Monitor the AGM outcome for any shareholder dissent on related-party compensation items, but no near-term trading catalyst is expected.

Key Facts

Annual General Meeting scheduled for June 16, 2026, with record date May 12, 2026.
Proposal to re-elect Rachel Guz-Lavi and elect Hagai Itkin as Class I directors.
CEO 2026 bonus plan targets include cash burn control, system sales (US and ex-US), fundraising, FDA study initiation, and factory relocation.
Discretionary 2025 bonus of NIS 77,625 (~$22,500) for CEO Dr. Elazar Sonnenschein and NIS 12,075 (~$3,500) for VP R&D Menashe Sonnenschein.
Amended compensation policy raises CEO max monthly salary from NIS 130,000 to NIS 200,000 and max annual bonus from NIS 780,000 to NIS 900,000.
Directors' annual fee set at NIS 509,000 (~$172,000) and per-meeting fee of NIS 4,000 (~$1,000).
Re-appointment of PwC as independent auditor for FY2026; audit fees were $184K in 2025 vs $56K in 2024.
Outstanding shares: 6,502,844 as of April 30, 2026; CEO/controlling shareholder owns 28.2%.

Financial Impact

No material financial impact. Discretionary bonuses total ~$26,000. Compensation policy increases are ceiling adjustments, not guaranteed payments.

Risk Factors

Potential shareholder dissent on CEO/controlling shareholder bonus plans and compensation increases.
CEO 2026 bonus plan includes a 20% weight on fundraising, signaling potential future dilution.

Market Snapshot

Exchange

Nasdaq

Sector

Surgical & Medical Instruments & Apparatus

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
6-K Filing (Primary)	0001493152-26-021745
Exhibit: ex99-2.htm	0001493152-26-021745
Document: form6-k.htm	0001493152-26-021745
Document: 0001493152-26-021745-index-headers.html	0001493152-26-021745
Document: 0001493152-26-021745-index.html	0001493152-26-021745
Document: 0001493152-26-021745.txt	0001493152-26-021745

US Market Status

Market Closed — Opens Thu (9h 47m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access